ALEXANDER KORCHMAREV: Open Payments
NPI 1821029042 · SHERMAN OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 28 payments from 7 companies in 2025. Trend: 2023 $690 · 2024 $822 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $238 |
| E.R. Squibb & Sons, L.L.C. | 5 | $154 |
| Lundbeck LLC | 4 | $116 |
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| Vanda Pharmaceuticals Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
Products named: CAPLYTA, REXULTI, COBENFY, FANAPT, TRINTELLIX, Qelbree.
Industry payments across CA — which companies pay providers there.
